Xbrane Set To Initiate Xlucane Study In US

Xbrane Biopharma has announced further progress for its lead biosimilar candidate, Xlucane (ranibizumab), with the FDA and the Central Ethics Committee in the US accepting the firm’s investigational new drug application, allowing the company’s ‘Xplore’ Phase III trial for the ophthalmology drug to begin.